Non-small cell lung cancers (NSCLCs) represent 85% of lung tumors. NSCLCs encompass
multiple cancer types, such as adenocarcinomas (LUADs), squamous cell cancers (LUSCs) …

Lung cancer is the leading cause of cancer death worldwide. Molecular targeted therapy
has greatly advanced the field of treatment for non-small cell lung cancer (NSCLC), which …

In order to explore the potential patient population who could benefit from anti PD-1/PD-L1
mono or combination therapies, this study aimed to profile a panel of immunotherapy related …

Continuous revision of the histologic and stage-wise classification of lung cancer by the
World Health Organization (WHO) provides the foundation for therapeutic advances by …

Background: Immune checkpoint inhibitors (ICIs), such as programmed cell death protein 1
(PD-1)/programmed death-ligand 1 (PD-L1), have been widely applied in clinical and …

Immune checkpoint inhibitors targeting the programmed cell death receptor/ligand 1 (PD-
1/PD-L1) pathway displayed striking and durable clinical responses in patients with non …

Background The underlying genetic alterations for squamous cell carcinoma (SCC) and
adenocarcinoma (AC) carcinogenesis are largely unknown. Methods High-resolution array …

Introduction The vascular endothelial growth factor A (VEGF) is the main mediator of
angiogenesis. In addition, VEGF contributes to cancer growth and metastasis directly …

The outcomes of patients with SCLC have not yet been substantially impacted by the
revolution in precision oncology, primarily owing to a paucity of genetic alterations in …

Manipulation of the immune response is a game changer in lung cancer treatment,
revolutionizing management. PD1 and CTLA4 are dynamically expressed on different T cell …